• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Patient Perspectives

Meet T.J. Sharpe

Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.

By
T.J. Sharpe
Feb 24, 2017

t-j-sharpe-is-a-melanoma-survivor-blogger-cancer-advocate
T.J. Sharpe, Melanoma survivor, Blogger & Cancer Advocate

Novartis has asked me to share my story here, relating to my ongoing battle with melanoma, and to share some of my experiences and physical, mental, and emotional hurdles that came hand in hand with managing a deadly disease. 

In August of 2012, I checked into the local ER with a spiking fever… and left 16 days later with a Stage IV melanoma diagnosis.  I was 37.  My wife had given birth to our second child just weeks before. And now I was facing the biggest obstacle imaginable to me being a good Dad and supportive husband – remaining alive.

The treating oncologist told my wife Jen that he would be surprised if I “were still here in 2 years,” as he suggested standard of care chemotherapy.  That was not good enough; 2 years barely gets little Tommy to remember his Daddy. We got 4 second opinions before finally settling on a clinical trial in the Tampa, Florida area. That trial failed, but 4 years later, after 2 clinical trials, 4 immunotherapies, and 6 surgeries, I am on the cusp of having a complete response.  I remain on the second clinical trial by our home in Fort Lauderdale, Florida.

As I have gotten progressively better – my latest scans show stable disease in only 2 remaining spots – I have been fortunate to be able to reach out and help others.   In the midst of the first trial, I was asked to contribute to the Philly.com Health Section. That has opened up new avenues to fulfill one goal I set as I laid in that hospital bed in 2012: to make a difference in the lives of other patients. I expanded the blog to include cancer research and advocacy.  I speak about my experiences on clinical trials and with immunotherapies.  I even got the chance to moderate a Twitter chat with Troy Aikman and The University of Pennsylvania's Abramson Cancer Center for the Melanoma Just Got Personal awareness campaign.

The coming blog posts will mix personal experiences with cancer and melanoma-specific information. They will speak to the changes in cancer treatments on the horizon as targeted and immunotherapies become more widely approved, and true personalized medicine comes closer to fruition.  It will talk about some of the impact that a cancer diagnosis will have on the patients – and their families. We’ll break down the clinical trial process, and stress why they are so important for medical research and for patients who need all available treatment options.

Novartis and I hope this series will be informative, authentic, and insightful – a real-life portrayal of the challenges faced during a fight for life. One in every 2 men and one in every 3 women in the United States will get cancer in their lifetime. It is going to happen to you or someone you care about. You don't need to know everything about cancer now, but it certainly will help to know where to find some basics relayed from someone who has walked a similar path.

This is the first installment in a series of blog posts authored by patient and advocate T.J. Sharpe for Novartis.com. Be sure to check back regularly for new installments in this series by T.J. Sharpe.

Tags: 
Cancer, Oncology, Patient Voices, Social Commitment, Targeted Therapy, Clinical Trials

T.J. Sharpe

T.J. Sharpe

is a Melanoma survivor, Blogger & Cancer Advocate.

Disclaimer: 

T.J. Sharpe is not a medical professional, but a patient currently undergoing care for advanced melanoma. He is being compensated by Novartis Oncology for sharing his story. All opinions are his own. Any and all information, tips, advice, etc. included throughout his series of blogs stem from his own personal experience as a patient. Patients should always consult their doctors when seeking medical advice.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Couple looking a digital devices outside
Patient Perspectives

Digital innovation looks set to dominate the 2021 healthcare agenda

A woman, accompanied by her caregiver, shares her experiences with a doctor.
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Chinese family embracing exercise and the outdoors
Patient Perspectives

AI Nurse evolving for health failure patients in China

You are here

  1. Home ›
  2. Stories ›
  3. Patient Perspectives

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.